Development of Redox Controlling Nanomedicine Based on Albumin Fusion

利用白蛋白融合技术，设计了一种新型的氧化还原控制纳米药物，并对其在临床上的应用进行了评估。多项研究的结果表明，HSA-硫氧还蛋白融合蛋白在治疗氧化应激和炎症相关疾病方面具有巨大的潜力。此外，SNO-HSA二聚体的EPR效应具有显著的肿瘤转移活性已得到证实。根据目前的研究结果，由临床医生领导的临床试验的准备工作目前正在进行中。

Using albumin fusion technology, a novel redox controlling nanomedicine was designed and evaluated for applications in clinical settings. The results from various studies suggested that HSA-thioredoxin fusion protein has great potential as a therapeutic agent for treating oxidative stress and inflammation related diseases. In addition, a significant tumor metastasis activity from the EPR effect of SNO-HSA dimer has been confirmed. Based on the results of the current studies, preparations for a clinical trial led by a clinician are now in progress.